{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-123481","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2023-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.768417+00:00","generated_at":"2026-06-07T17:40:49.707909+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Novavax reaches $47M settlement in principle to resolve securities class action","bullets":["Company agreed to pay $47M into settlement fund; expects D&O insurance to fund it.","Settlement resolves surviving claims about alleged false statements on vaccine manufacturing and regulatory approval.","Class period: February 24, 2021 to October 19, 2021; court approval required.","Settlement includes customary releases and a disclaimer of liability by Novavax and named executives.","Previously, court dismissed some claims but allowed others to proceed; parties now seek to end litigation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-123481","json":"https://secwatch.observer/filing/0001104659-23-123481.json","markdown":"https://secwatch.observer/filing/0001104659-23-123481.md","text":"https://secwatch.observer/filing/0001104659-23-123481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923123481/0001104659-23-123481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923123481/tm2332186d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T17:40:49.707909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}